Published in September 2021, this study in the journal Cannabis & Cannabinoid Research, looked at self-reported therapeutic effects of CBG products (containing more than 50% CBG). There are even CBG dominant hemp cigarettes available in the USA.
The study recruited 127 participants that had used CBG dominant products in the last 6 months. The most common conditions reported were anxiety, chronic pain, depression, & insomnia.
"Efficacy was highly rated, with the majority reporting their conditions were 'very much improved' or 'much improved' by CBG."
The majority of patients reported that the CBG products were superior to conventional treatments: Chronic pain (74%), Depression (80%), Insomnia (73%), & Anxiety (78%).
This is "the first [study] to document self-reported efficacy of CBG-predominant products, particularly for anxiety, chronic pain, depression, and insomnia. Most respondents reported greater efficacy of CBG-predominant cannabis over conventional pharmacotherapy, with a benign adverse event profile and negligible withdrawal symptoms."